Minerva Neurosciences | NERV - Ebitda


Minerva Neurosciences reported $-4.36M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Adma Biologics USD 55.44M 5.62M Jun/2026
ALKERMES USD 120.06M 19.15M Sep/2026
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
AstraZeneca USD 7.46B 2.3B Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Cipla INR 13.88B 154.2M Sep/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -8.84M 180K Jun/2026
CSL USD 3.13B 1.17B Dec/2025
Eli Lilly USD 9.46B 3.54B Sep/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
J&J USD 8.99B 721M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novartis USD 8.62B 2.14B Sep/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.36B 350M Sep/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Takeda JPY 369.75B 5.29B Sep/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024